Correspondence 0000950170-24-098401 from Evoke Pharma Inc (EVOK) (CIK 0001403708)
Evoke Pharma Inc (EVOK) (CIK 0001403708)
Date: Aug. 19, 2024 · CIK: 0001403708 · Accession: 0000950170-24-098401
AI Filing Summary & Sentiment
File numbers found in text: 333-281527
Letter
Evoke Pharma, Inc.
420 Stevens Avenue, Suite 230
Solana Beach, CA 92075
August 19, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Evoke Pharma, Inc.
Registration Statement on Form S-3
File No. 333-281527
To the addressees set forth above:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Evoke Pharma, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on August 21, 2024, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter.
Very truly yours,
EVOKE PHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 August 19, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-3 File No. 333-281527 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Evoke Pharma, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on August 21, 2024, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter. Very truly yours, EVOKE PHARMA, INC. By: /s/ Matthew J. D’Onofrio Matthew J. D’Onofrio Chief Executive Officer cc: Mark Kowieski, Evoke Pharma, Inc. Cheston J. Larson, Latham & Watkins LLP Matthew T. Bush, Latham & Watkins LLP Anthony A. Gostanian, Latham & Watkins LLP